|
ranibizumab |
5 |
|
age-related macular degeneration |
4 |
|
half-dose |
4 |
|
half-fluence |
4 |
|
photodynamic therapy |
4 |
|
polypoidal choroidal vasculopathy |
4 |
|
verteporfin |
4 |
|
adult |
3 |
|
aged |
3 |
|
best corrected visual acuity |
3 |
|
clinical article |
3 |
|
controlled study |
3 |
|
conventional glycemic control |
3 |
|
diabetic retinopathy |
3 |
|
insulin dependent diabetes mellitus |
3 |
|
intense glycemic control |
3 |
|
non insulin dependent diabetes mellitus |
3 |
|
aflibercept |
2 |
|
macular degeneration |
2 |
|
phacoemulsification |
2 |
|
phacovitrectomy surgery |
2 |
|
premium intraocular lens |
2 |
|
vascular endothelial growth factors |
2 |
|
vitrectomy |
2 |
|
anti-vegf |
1 |
|
choroidal neovascularization |
1 |
|
myopia |
1 |
